Base de datos : MEDLINE
Búsqueda : D27.505.519.389.745.800.449 [Categoria DeCS]
Referencias encontradas : 5488 [refinar]
Mostrando: 1 .. 10   en el formato [Largo]

página 1 de 549 va a la página                         

  1 / 5488 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
PMID:29292966
Autor:Lindeman E
Dirección:Läkemedelsverket - Giftinformationscentralen Stockholm, Sweden Läkemedelsverket - Giftinformationscentralen Stockholm, Sweden.
Título:Målstyrd antidotterapi vid reversering av dabigatran..
Fuente:Lakartidningen; 114, 2017 Dec 05.
ISSN:1652-7518
País de publicación:Sweden
Idioma:swe
Resumen:Goal-directed administration of antidote for reversal of dabigatran anticoagulation Idarucizumab is a monoclonal antibody fragment that acts as an antidote to dabigatran. Idarucizumab is indicated in dabigatran-associated serious bleeds and to reverse dabigatran anticoagulation before acute surgical interventions or invasive medical procedures. The recommended dose of 5 g idarucizumab is sufficient to achieve a lasting restoration of coagulation in most patients. In a number of cases however, notably in deliberate overdoses and in accumulation of dabigatran in renal failure, repeated doses of idarucizumab may be necessary to avoid persisting or rebound anticoagulation. This article gives a brief explanation of the mechanisms responsible for this phenomenon and argues that it should be anticipated. Serial monitoring of APTT or dTT in patients treated with idarucizumab should enable the early detection of treatment failure or rebound anticoagulation and, if clinically indicated, prompt administration of additional doses of antidote.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antibodies, Monoclonal, Humanized); 0 (Antidotes); 0 (Antithrombins); 97RWB5S1U6 (idarucizumab); I0VM4M70GC (Dabigatran)


  2 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29231667
Autor:Myrstad M; Vandvik I; Engebretsen EH; Tveit A
Título:Hjerneslag etter seponering av nye antikoagulasjonsmidler før kirurgi..
Fuente:Tidsskr Nor Laegeforen; 137(23-24), 2017 12 12.
ISSN:0807-7096
País de publicación:Norway
Idioma:nor
Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
Nombre de substancia:0 (Anticoagulants); 0 (Antithrombins); 0 (Factor Xa Inhibitors); 0 (Pyrazoles); 0 (Pyridones); 3Z9Y7UWC1J (apixaban); I0VM4M70GC (Dabigatran)


  3 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27770581
Autor:Walters KJ; Meador A; Galdo JA; Ciarrocca K
Dirección:PGY-1 Community Resident, Samford University, Birmingham, AL.
Título:A pharmacotherapy review of the novel, oral antithrombotics.
Fuente:Spec Care Dentist; 37(2):62-70, 2017 Mar.
ISSN:1754-4505
País de publicación:United States
Idioma:eng
Resumen:Coagulation disorders account for a high incidence of death in the U.S. due to stroke, myocardial infarction, and venous thromboembolism. In the past few years, numerous agents have been brought to market for the treatment of thromboembolism or prevention of thromboembolism. Similar to warfarin, these agents can cause bleeding disorders, which may exacerbate dental care treatment plans. This literature review examines the newer agents for the treatment of thromboembolism disorders, common side effects and drug interactions, the specific medical conditions each agent treats, and the dental perspective on how to medically management patients prescribed these medications.
Tipo de publicación:JOURNAL ARTICLE; REVIEW
Nombre de substancia:0 (Antithrombins)


  4 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29279522
Autor:Wakakura S; Hara F; Fujino T; Hamai A; Ohara H; Kabuki T; Harada M; Ikeda T
Dirección:Department of Cardiovascular Medicine, Toho University Faculty of Medicine.
Título:Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase.
Fuente:Int Heart J; 59(1):126-135, 2018 Jan 27.
ISSN:1349-3299
País de publicación:Japan
Idioma:eng
Resumen:We assessed the efficacy and safety of direct oral anticoagulants (DOACs) for the treatment of deep venous thrombosis (DVT) in the chronic phase through comparison with conventional warfarin therapy.A total of 807 consecutive patients who were diagnosed with having DVT in the chronic phase were included (484 patients to warfarin therapy and 323 patients to DOAC therapy). The condition of leg veins was assessed 3 to 6 months after starting the therapies by ultrasound examination. Major bleeding and mortality during the therapies were followed-up.There was no significant difference between the two groups in the thrombosis improvement rate (DOAC group: 91.2% versus warfarin group: 88.9%). There was no significant difference between the two groups in major bleeding (DOAC group: 1.8% versus warfarin group: 1.8%). In patients with active cancer, the DOAC group had a borderline higher thrombosis improvement rate than the warfarin group (92.1% versus 80.0%, P = 0.05). The proportion of major bleeding in the patients with active cancer was slightly higher in the warfarin group than in the DOAC group (4.3% versus 2.8%; P = 0.71). Active cancer was not an independent risk factor for major bleeding and recurrence in the DOAC group (OR 2.68, 95% CI 0.51-14.1; P = 0.24 and OR 0.65, 95% CI 0.20-2.07; P = 0.47).In treatment using oral anticoagulants for DVT in the chronic phase, DOACs exhibited equal efficacy and safety as warfarin did. Particularly DOACs appear to be an attractive therapeutic option for cancer-associated DVT in chronic phase, with relatively low anticipated rates of recurrence and major bleeding.
Tipo de publicación:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
Nombre de substancia:0 (Anticoagulants); 0 (Antithrombins); 0 (Factor Xa Inhibitors); 0 (Pyrazoles); 0 (Pyridines); 0 (Pyridones); 0 (Thiazoles); 3Z9Y7UWC1J (apixaban); 5Q7ZVV76EI (Warfarin); I0VM4M70GC (Dabigatran); NDU3J18APO (edoxaban)


  5 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28456636
Autor:Ramjee MK; Patel S
Dirección:Cyclofluidic Limited, BioPark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom. Electronic address: manoj.ramjee@cyclofluidic.co.uk.
Título:Continuous-flow injection microfluidic thrombin assays: The effect of binding kinetics on observed enzyme inhibition.
Fuente:Anal Biochem; 528:38-46, 2017 07 01.
ISSN:1096-0309
País de publicación:United States
Idioma:eng
Resumen:A microfluidic assay for monitoring the inhibition of thrombin peptidase activity was developed. The system, which utilised soluble reagents in continuous-flow injection mode, was configured so as to allow inhibitor titrations via gradient formation. This microfluidic continuous-flow injection titration assay (CFITA) enabled the potency of a set of small-molecule serine peptidase inhibitors (SPIs) to be evaluated. The results, compared to standard microtiter plate (MTP) data, indicated that a microfluidic CFITA provided an efficient and effective method for evaluating compound potency. Crucially, whereas for fast-acting compounds the rank order of potency between the CFITA and MTP methods was preserved, for slow-acting compounds the observed CFITA potencies were significantly lower. These results, in conjunction with data from computer simulations, clearly demonstrated that continuous-flow assays, and perhaps microfluidic assays in general, must take into account binding kinetics when used to assess reaction criteria.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antithrombins); EC 3.4.21.5 (Thrombin)


  6 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29342377
Autor:Erlinge D; James S
Dirección:Lund University, Lund, Sweden david.erlinge@med.lu.se
Título:Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
Fuente:N Engl J Med; 378(3):300, 2018 01 18.
ISSN:1533-4406
País de publicación:United States
Idioma:eng
Tipo de publicación:LETTER; COMMENT
Nombre de substancia:0 (Anticoagulants); 0 (Antithrombins); 0 (Hirudins); 0 (Peptide Fragments); 0 (Recombinant Proteins); 9005-49-6 (Heparin); TN9BEX005G (bivalirudin)


  7 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo SciELO Chile
PMID:29189853
Autor:Corbalán R; Conejeros C; Rey C; Stockins B; Eggers G; Astudillo C; Lanas F; Potthoff S; Houzvic C; Montecinos H; Charme G; Bugueño C; Aguilar J; Arriagada G; Marín P; Larico M
Dirección:División Enfermedades Cardiovasculares, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Título:[Features, management and prognosis of Chilean patients with non valvular atrial fibrillation: GARFIELD AF registry].
Título:Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile..
Fuente:Rev Med Chil; 145(8):963-971, 2017 Aug.
ISSN:0717-6163
País de publicación:Chile
Idioma:spa
Resumen:BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of anti-thrombotic therapies in Chilean patients with non-valvular AF. AIM: To describe the characteristics and 1-year outcomes of patients with recently diagnosed AF recruited in Chile into the prospective global GARFIELD-AF registry. MATERIAL AND METHODS: Between 2011-2016, we prospectively registered information of 971 patients recruited at 15 centers, 85% of them from the public system and 15% from the private sector. Demographics, clinical characteristics and use of antithrombotic therapies were recorded for all patients. Adverse clinical outcomes were analyzed in 711 patients with 1-year follow-up. RESULTS: The mean age was 71.5 years (66-79), 50% were men. Mean CHAD2S2 Vasc and HAS BLED scores for stroke risk were 3.3 (2.0-4.0) and 1.5 (1.0-2.0) respectively. Oral anticoagulants were prescribed in 82% of patients. Seventy percent received Vitamin K antagonists, 10% novel direct anticoagulants or antiplatelet therapy and only 8% did not receive any antithrombotic therapy. Mean time in optimal therapeutic range (an international normalized ratio of 2 to 3), was achieved in only 40.7% (23.0-54.8) of patients receiving Vitamin K antagonists. One year rates of death, stroke/systemic embolism and bleeding were 4.75 (3.36-6.71), 2.40 (1.47-3.92) and 1.64% (0.91-2.97) per 100 person-years. Ischemic stroke occurred in 1.8% and hemorrhagic stroke in 0.8% of patients at 1-year of follow up. CONCLUSIONS: Although the use of vitamin K antagonists at baseline was high, the mean time in optimal therapeutic range was low. Mortality and stroke rates are higher than those reported in other contemporary registries.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antithrombins); 0 (Factor Xa Inhibitors); 0 (Fibrinolytic Agents); 0 (Platelet Aggregation Inhibitors); 12001-79-5 (Vitamin K)


  8 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29223437
Autor:Qaderdan K; Vos GA; McAndrew T; Steg PG; Hamm CW; Van't Hof A; Mehran R; Deliargyris EN; Bernstein D; Stone GW; Ten Berg JM
Dirección:St. Antonius Hospital, Department of Cardiology, Nieuwegein, The Netherlands.
Título:Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
Fuente:Am Heart J; 194:73-82, 2017 Dec.
ISSN:1097-6744
País de publicación:United States
Idioma:eng
Resumen:BACKGROUND: Since older age is a strong predictor of not only bleeding but also of ischemic events, understanding the risk:benefit profile of bivalirudin in the elderly undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation (STEMI) is important. For this, we aim to compare elderly with young patients, who all underwent pPCI for STEMI and randomly received either bivalirudin or heparin. METHODS: We performed a patient-level pooled analysis (n=5800) of two large randomized trials. A total of 2149 (37.1%) elderly patients (>65 years of age) with STEMI were enrolled and randomly assigned to either bivalirudin or heparin with or without a GPI (control group) before pPCI. Clinical outcomes at 30 days were analyzed. RESULTS: In elderly patients, bivalirudin significantly reduced non-CABG major bleeding (7.1% vs 10.4%; P<.01), subacute ST (0.4% vs 1.5%; P<.01), and net adverse clinical events (NACE; composite of all-cause mortality, reinfarction, IDR, stroke or protocol-defined non-CABG major bleeding [13.7% vs 17.2%; P=.03]) with comparable rates of stroke, MI, acute ST, or all-cause death, when compared with heparin with or without GPI. CONCLUSIONS: In a large group of elderly patients enrolled in the EUROMAX and HORIZONS-AMI trials, bivalirudin was associated with lower 30-day rates of non-CABG major bleeding, subacute ST and NACE, with similar 30-day rates of acute ST and mortality.
Tipo de publicación:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
Nombre de substancia:0 (Antithrombins); 0 (Fibrinolytic Agents); 0 (Hirudins); 0 (Peptide Fragments); 0 (Recombinant Proteins); 9005-49-6 (Heparin); TN9BEX005G (bivalirudin)


  9 / 5488 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29082734
Autor:Sorigue M
Dirección:Institut Català d'Oncologia, Badalona, Spain msorigue@iconcologia.net
Título:Dabigatran Reversal with Idarucizumab.
Fuente:N Engl J Med; 377(17):1691, 2017 10 26.
ISSN:1533-4406
País de publicación:United States
Idioma:eng
Tipo de publicación:LETTER; COMMENT
Nombre de substancia:0 (Antibodies, Monoclonal, Humanized); 0 (Antithrombins); 97RWB5S1U6 (idarucizumab); I0VM4M70GC (Dabigatran)


  10 / 5488 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29082732
Autor:Yip L; Deng JF
Dirección:Rocky Mountain Poison and Drug Center, Denver, CO luke.yip@rmpdc.org
Título:Dabigatran Reversal with Idarucizumab.
Fuente:N Engl J Med; 377(17):1690, 2017 10 26.
ISSN:1533-4406
País de publicación:United States
Idioma:eng
Tipo de publicación:LETTER; COMMENT
Nombre de substancia:0 (Antibodies, Monoclonal, Humanized); 0 (Antithrombins); 97RWB5S1U6 (idarucizumab); I0VM4M70GC (Dabigatran)



página 1 de 549 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud